MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

49.55 4.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

47.4

Максимум

49.77

Ключови измерители

By Trading Economics

Приходи

-34M

-248M

Марж на печалбата

-74.379

Служители

700

EBITDA

-24M

-261M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+57.58% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.2B

9.1B

Предишно отваряне

45.39

Предишно затваряне

49.55

Настроения в новините

By Acuity

50%

50%

166 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.10.2025 г., 23:25 ч. UTC

Значими двигатели на пазара

Salesforce Rises on New FY30 Financial Targets

15.10.2025 г., 18:52 ч. UTC

Печалби
Значими двигатели на пазара

Prologis Shares Gain on Raised Outlook, Data Center Growth

15.10.2025 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software to Buy U.K.'s Tecvia Holding

15.10.2025 г., 17:19 ч. UTC

Придобивния, сливания и поглъщания

Drahi's Altice Rejects $20 Billion Joint Offer From Peers -- 2nd Update

15.10.2025 г., 17:11 ч. UTC

Придобивния, сливания и поглъщания

Anglo American, MMG Offer Concessions to EU Merger Watchdog in Nickel Deal Probe

15.10.2025 г., 23:48 ч. UTC

Пазарно говорене

Gold Steady, Supported by Expectations of Ongoing Central Bank Purchases -- Market Talk

15.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15.10.2025 г., 22:37 ч. UTC

Пазарно говорене

Economic Stars Are Aligning for RBA -- Market Talk

15.10.2025 г., 21:44 ч. UTC

Печалби

Stock Rally Is Lifting Wealth Managers. How Much Is Charles Schwab Benefiting? -- Barrons.com

15.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Recommends Hldrs Do Not Tender Their Shrs to the Offer >QSR.T

15.10.2025 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer to Buy Shrs at $28.80/Shr

15.10.2025 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Restaurant Brands Notified of Unsolicited Mini-Tender Offer by NY Stk and Bond LLC to Purchase Up to 10,000 Common Shrs >QSR.T

15.10.2025 г., 20:34 ч. UTC

Печалби

Prologis Raises Outlook as Warehouse Leasing Picks Up -- WSJ

15.10.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

RBI Recommends Hldrs Reject NYSB's "Mini-Tender Offer"

15.10.2025 г., 20:17 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova Stock Feill With Latest Call to Sell -- Barrons.com

15.10.2025 г., 19:06 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Bank of America, Morgan Stanley, ASML, AMD, Nvidia, Bunge, Progressive, Abbott, and More -- Barrons.com

15.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Post Back-to-Back Losses -- Market Talk

15.10.2025 г., 18:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

15.10.2025 г., 18:23 ч. UTC

Печалби

This Insurer Is the One of the Worst Stocks in the S&P 500 Today. Here's Why. -- Barrons.com

15.10.2025 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software's Harris Operating Group Enters Into Agreement To Acquire TECVIA Holding GmbH >CSU.T

15.10.2025 г., 17:34 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Trade, Oversupply Concerns -- Market Talk

15.10.2025 г., 16:57 ч. UTC

Печалби

The Nation's Biggest Banks Are Saying the Economy Is Still Strong -- WSJ

15.10.2025 г., 16:51 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Doesn't Disclose Financial Details

15.10.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: RetinAI Partners With Pharmaceutical Companies, Research Organizations

15.10.2025 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Deal Reinforces the Group's Med-Tech Journey

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Specializes in Artificial Intelligence, Data Management in Eyecare

15.10.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica: Ikerian Is a Health Technology Company, Operating Under the RetinAI Brand

15.10.2025 г., 16:47 ч. UTC

Придобивния, сливания и поглъщания

EssilorLuxottica Buys Ikerian

15.10.2025 г., 16:34 ч. UTC

Пазарно говорене

AMD Data Center Agreements Will Provide Big Revenue Growth -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

57.58% нагоре

12-месечна прогноза

Среден 74.85 USD  57.58%

Висок 85 USD

Нисък 66 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

16

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

40.67 / 41.96Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

166 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat